Applied Therapeutics reports Q2 loss of $21.3M; advances CMT-SORD govorestat NDA meeting with FDA

Applied Therapeutics, Inc.

2025-Q2 EPS reported -$0.30

Net loss $21.3M ($0.15/share) vs net income $2.9M in Q2 2024; cash $30.4M down from $79.4M.
FDA meeting scheduled Q3 2025 to discuss govorestat NDA submission for CMT-SORD.
Launched free urine sorbitol assay in July 2025 to identify CMT-SORD patients.
Out-licensed AT-001 to Biossil for upfront and milestone payments; promoted Bailey to CMO and Caplan to EVP.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.